IRAK4-IN-17 (Compound 5) 是一种强效IRAK4抑制剂，IC50为 1.3 nM。IRAK4-IN-17 可用于弥漫性大 B 细胞淋巴瘤 (DLBCL) 研究。

IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC 50 of 1.3 nM [1]. IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research [1].

IRAK4-IN-17 (0.7-40.1 μM; 72 h) selectively suppresses OCI-LY10 and TMD8 cells with MYD88 L265P mutation [1]. IRAK4-IN-17 (0.3-10 μM; 2 h) inhibits the viability of DLBCL cells by targeting IRAK4 signaling [1]. Cell Cytotoxicity Assay [1] Cell Line: OCI-LY10, TMD8, Ramos and HT cells Concentration: 0.7-40.1 μM Incubation Time: 72 hours Result: Suppressed OCI-LY10 and TMD8 cells with MYD88 L265P mutation (IC 50 =0.7 μM and 1.2 μM, respectively), but not Ramos and HT cell lines with WT MYD88 (IC 50 =11.4 μM and 40.1 μM, respectively). Western Blot Analysis [1] Cell Line: OCI-LY10 and TMD8 cells Concentration: 0.3, 1, 3 and 10 μM Incubation Time: 2 hours Result: Inhibited the phosphorylation of IRAK4 and the downstream molecules, IKKβ and NF-κB transcription factor (p65) in OCI-LY10 and TMD8 cells.

2183503-33-3

C17H20F2N8O

390.39

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years